1539 related articles for article (PubMed ID: 33722534)
1. Addressing the role of 11β-hydroxysteroid dehydrogenase type 1 in the development of polycystic ovary syndrome and the putative therapeutic effects of its selective inhibition in a preclinical model.
Li X; Hu S; Zhu Q; Yao G; Yao J; Li J; Wang Y; Ding Y; Qi J; Xu R; Zhao H; Zhu Z; Du Y; Sun K; Sun Y
Metabolism; 2021 Jun; 119():154749. PubMed ID: 33722534
[TBL] [Abstract][Full Text] [Related]
2. The upregulation of 11β-HSD1 in ovarian granulosa cells by cortisol and interleukin-1β in polycystic ovary syndrome.
Wu H; Zhu Q; Li X; He Y; Wang Y; Lu Y; Qi J; Ding Y; Li J; Xu R; Sun Y
Gynecol Endocrinol; 2020 Aug; 36(8):668-672. PubMed ID: 31902257
[TBL] [Abstract][Full Text] [Related]
3. Local Regeneration of Cortisol by 11β-HSD1 Contributes to Insulin Resistance of the Granulosa Cells in PCOS.
Zhu Q; Zuo R; He Y; Wang Y; Chen ZJ; Sun Y; Sun K
J Clin Endocrinol Metab; 2016 May; 101(5):2168-77. PubMed ID: 26934392
[TBL] [Abstract][Full Text] [Related]
4. 11β-Hydroxysteroid dehydrogenase type 1 selective inhibitor BVT.2733 protects osteoblasts against endogenous glucocorticoid induced dysfunction.
Wu L; Qi H; Zhong Y; Lv S; Yu J; Liu J; Wang L; Bi J; Kong X; Di W; Zha J; Liu F; Ding G
Endocr J; 2013; 60(9):1047-58. PubMed ID: 23759754
[TBL] [Abstract][Full Text] [Related]
5. Adipose tissue-targeted 11β-hydroxysteroid dehydrogenase type 1 inhibitor protects against diet-induced obesity.
Liu J; Wang L; Zhang A; Di W; Zhang X; Wu L; Yu J; Zha J; Lv S; Cheng P; Hu M; Li Y; Qi H; Ding G; Zhong Y
Endocr J; 2011; 58(3):199-209. PubMed ID: 21325744
[TBL] [Abstract][Full Text] [Related]
6. BVT.2733, a selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor, attenuates obesity and inflammation in diet-induced obese mice.
Wang L; Liu J; Zhang A; Cheng P; Zhang X; Lv S; Wu L; Yu J; Di W; Zha J; Kong X; Qi H; Zhong Y; Ding G
PLoS One; 2012; 7(7):e40056. PubMed ID: 22768329
[TBL] [Abstract][Full Text] [Related]
7. Ovarian 11β-hydroxysteroid dehydrogenase (11βHSD) activity is suppressed in women with anovulatory polycystic ovary syndrome (PCOS): apparent role for ovarian androgens.
Michael AE; Glenn C; Wood PJ; Webb RJ; Pellatt L; Mason HD
J Clin Endocrinol Metab; 2013 Aug; 98(8):3375-83. PubMed ID: 23678035
[TBL] [Abstract][Full Text] [Related]
8. Altered cortisol metabolism in polycystic ovary syndrome: insulin enhances 5alpha-reduction but not the elevated adrenal steroid production rates.
Tsilchorozidou T; Honour JW; Conway GS
J Clin Endocrinol Metab; 2003 Dec; 88(12):5907-13. PubMed ID: 14671189
[TBL] [Abstract][Full Text] [Related]
9. 11β-Hydroxysteroid dehydrogenase 1 inhibition attenuates collagen-induced arthritis.
Zhang L; Dong Y; Zou F; Wu M; Fan C; Ding Y
Int Immunopharmacol; 2013 Nov; 17(3):489-94. PubMed ID: 23938253
[TBL] [Abstract][Full Text] [Related]
10. Expression of 11beta-hydroxysteroid dehydrogenase 1 and 2 in subcutaneous adipose tissue of lean and obese women with and without polycystic ovary syndrome.
Svendsen PF; Madsbad S; Nilas L; Paulsen SK; Pedersen SB
Int J Obes (Lond); 2009 Nov; 33(11):1249-56. PubMed ID: 19704410
[TBL] [Abstract][Full Text] [Related]
11. Local Cortisol Elevation Contributes to Endometrial Insulin Resistance in Polycystic Ovary Syndrome.
Qi J; Wang W; Zhu Q; He Y; Lu Y; Wang Y; Li X; Chen ZJ; Sun Y
J Clin Endocrinol Metab; 2018 Jul; 103(7):2457-2467. PubMed ID: 29618067
[TBL] [Abstract][Full Text] [Related]
12. Selective Inhibition of 11β-Hydroxysteroid Dehydrogenase Type 1 Attenuates High-Fat Diet-Induced Hepatic Steatosis in Mice.
Li H; Sheng J; Wang J; Gao H; Yu J; Ding G; Ding N; He W; Zha J
Drug Des Devel Ther; 2021; 15():2309-2324. PubMed ID: 34103895
[TBL] [Abstract][Full Text] [Related]
13. Piperazine sulfonamides as potent, selective, and orally available 11beta-hydroxysteroid dehydrogenase type 1 inhibitors with efficacy in the rat cortisone-induced hyperinsulinemia model.
Xiang J; Wan ZK; Li HQ; Ipek M; Binnun E; Nunez J; Chen L; McKew JC; Mansour TS; Xu X; Suri V; Tam M; Xing Y; Li X; Hahm S; Tobin J; Saiah E
J Med Chem; 2008 Jul; 51(14):4068-71. PubMed ID: 18578516
[TBL] [Abstract][Full Text] [Related]
14. 11beta-hydroxysteroid dehydrogenase type 1 and obesity.
Morton NM; Seckl JR
Front Horm Res; 2008; 36():146-164. PubMed ID: 18230901
[TBL] [Abstract][Full Text] [Related]
15. 11beta-Hydroxysteroid dehydrogenase type 1 inhibitors: novel agents for the treatment of metabolic syndrome and obesity-related disorders?
Anagnostis P; Katsiki N; Adamidou F; Athyros VG; Karagiannis A; Kita M; Mikhailidis DP
Metabolism; 2013 Jan; 62(1):21-33. PubMed ID: 22652056
[TBL] [Abstract][Full Text] [Related]
16. Active site variability of type 1 11beta-hydroxysteroid dehydrogenase revealed by selective inhibitors and cross-species comparisons.
Hult M; Shafqat N; Elleby B; Mitschke D; Svensson S; Forsgren M; Barf T; Vallgårda J; Abrahmsen L; Oppermann U
Mol Cell Endocrinol; 2006 Mar; 248(1-2):26-33. PubMed ID: 16431016
[TBL] [Abstract][Full Text] [Related]
17. Modulation of steroidogenesis by vitamin D3 in granulosa cells of the mouse model of polycystic ovarian syndrome.
Bakhshalizadeh S; Amidi F; Alleyassin A; Soleimani M; Shirazi R; Shabani Nashtaei M
Syst Biol Reprod Med; 2017 Jun; 63(3):150-161. PubMed ID: 28345956
[TBL] [Abstract][Full Text] [Related]
18. Dehydroepiandrosterone with a high-fat diet treatment at inducing polycystic ovary syndrome in rat model.
He Y; Li X; Li Y; Kuai D; Zhang H; Wang Y; Tian W
Steroids; 2024 Jun; 206():109424. PubMed ID: 38642598
[TBL] [Abstract][Full Text] [Related]
19. Endogenous inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 do not explain abnormal cortisol metabolism in polycystic ovary syndrome.
Walker BR; Rodin A; Taylor NF; Clayton RN
Clin Endocrinol (Oxf); 2000 Jan; 52(1):77-80. PubMed ID: 10651756
[TBL] [Abstract][Full Text] [Related]
20. 11Beta-hydroxysteroid dehydrogenase type 1 in human disease: a novel therapeutic target.
Tomlinson JW
Minerva Endocrinol; 2005 Mar; 30(1):37-46. PubMed ID: 15877012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
